MBX · MBX Biosciences Inc
United States · RS rating 56 · As of 2026-10-14
| Price | 48.82 USD |
|---|---|
| 1-day change | -0.4% |
| RS rating (overall / 1M / 3M / 12M) | 56 / 11 / 23 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 40 / 48 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +22.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +30.9% |
| Market cap (USD) | $1.6B |